ReviewRheumatology (Oxford, England)2020
Treatment targets in SLE: remission and low disease activity state.
Review in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity.Lupus science & medicine · 2023Pooled it
- Trial
- Advancing treat-to-target in SLE: a pilot study using a clinical decision support system.Lupus science & medicine · 2025Trial
- Redefining Difficult-to-Treat Systemic Lupus Erythematosus: Biomarkers of Molecular Refractoriness Beyond Clinical Failure.International journal of molecular sciences · 2026Review
- The emerging role of TLR7-mediated signaling in respiratory viral infections and autoimmune diseases.Cellular and molecular life sciences : CMLS · 2026Review
- Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC-MS/MS.Scientific reports · 2025Article
- Article
- Article
- Validity of a claim-based algorithm for classifying disease activity levels using Systemic Lupus Erythematosus Disease Activity Index 2000 in Korean patients with systemic lupus erythematosus.Journal of rheumatic diseases · 2025Article
- Observational
- Biomarkers in Lupus Nephritis: An Evidence-Based Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Achievement and Features Associated with Childhood Definition of Remission in Juvenile-Onset Systemic Lupus Erythematosus.Turkish archives of pediatrics · 2025Article
- Elevated serum interferon-α2 associates with activity and flare risk in juvenile-onset systemic lupus erythematosus.Rheumatology (Oxford, England) · 2025Article
- Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes.Lupus science & medicine · 2025Article
- Belimumab 10 years later: how drug positioning has changed.Immunologic research · 2024Article
- Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus.Journal of translational autoimmunity · 2024Review
- Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Clinical Features and Survival Analysis of Lupus Nephritis among Patients with Systemic Lupus Erythematosus: A Three-Decade-Long Retrospective Cohort Study.Biomedicines · 2024Article
- Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.Mediterranean journal of rheumatology · 2024Review
- Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states.Arthritis research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treat-to-target strategies have changed the approach to management of many chronic conditions, with improvements in patient outcomes. The key to success of treat to target is the availability of validated treatment endpoints, which have been difficult to derive for SLE, a condition notorious for its heterogeneity. This review will focus on the development and validation of the definitions of remission in SLE framework and the lupus low disease activity state. Lupus low disease activity state is more attainable than remission, with a stepwise concentric relationship between the target states indicating increasing stringency. Both lupus low disease activity state and definitions of remission in SLE remission have been proven to be associated with reduction in disease flares, reduced risk of accrual of irreversible end organ damage, and improvement in patient reported outcomes. These endpoints have therefore provided the key for the development of a treat-to-target approach in clinical practice in SLE and for the design of future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.